<DOC>
	<DOCNO>NCT00928590</DOCNO>
	<brief_summary>The purpose study describe long-term safety fix combination product contain alternative preservative , dose daily 12 month , patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Study DuoTrav APS Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<criteria>Willing able sign inform consent document . Openangle glaucoma ocular hypertension would benefit fixed combination medication , opinion investigator . Stable treatment IOPlowering medication . Other protocoldefined inclusion criterion may apply . Pregnant , breastfeeding , use adequate birth control . Bestcorrected visual acuity ( BCVA ) worse 55 ETDRS letter . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>pseudoexfoliation</keyword>
	<keyword>pigment dispersion</keyword>
</DOC>